2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T733,Emerging evidence suggests that circadian timing influences the efficacy of immune checkpoint inhibitors (ICI), with morning infusions associated with improved therapeutic outcomes across various malignancies. However, the impact of ICI infusion timing on extensive-stage small cell lung cancer (ES-SCLC), a disease with poor prognosis and limited therapeutic advancements, remains unexplored. This retrospective study (LungTime-R02) analyzed 397 patients with ES-SCLC who received first-line anti-PD-L1 (atezolizumab or durvalumab) plus chemotherapy at our center between May 2019 and October 2023. The time of day of administration (ToDA) was calculated as the median infusion time for each patient's first four ICI treatment cycles. To assess its prognostic relevance, hazard ratios (HRs) of earlier progression or death were estimated across multiple ToDA thresholds (11:00-16:30). Propensity score matching (1:2) was applied to balance baseline characteristics. Of the 397 patients, the optimal ToDA cutoff for maximizing progression-free survival (PFS) benefit was identified as 15:00, with the lowest HR for PFS observed at this threshold. Patients who received immunochemotherapy before 15:00 exhibited significantly longer PFS and overall survival compared to those treated later, with results consistent across pooled and propensity score matching cohorts. Multivariable analysis confirmed early ToDA as an independent prognostic factor for both PFS (adjusted HR, 0.483; 95% CI, 0.357-0.654) and overall survival (adjusted HR, 0.373; 95% CI, 0.265-0.526). This study provides real-world evidence supporting the survival benefit of earlier immunochemotherapy administration in patients with ES-SCLC. These findings add to the growing body of knowledge on the clinical relevance of circadian timing in cancer treatment. Not applicable.31:Ta71,Abstract Background Emerging evidence suggests that circadian timing influences the efficacy of immune checkpoint inhibitors (ICI), with morning infusions associated with improved therapeutic outcomes across various malignancies. However, the impact of ICI infusion timing on extensive‐stage small cell lung cancer (ES‐SCLC), a disease with poor prognosis and limited therapeutic advancements, remains unexplored. Method This retrospective study (LungTime‐R02) analyzed 397 patients with ES‐SCLC who received first‐line anti–PD‐L1 (atezolizumab or durvalumab) plus chemotherapy at our center between May 2019 and October 2023. The time of day of administration (ToDA) was calculated as the median infusion time for each patient’s first four ICI treatment cycles. To assess its prognostic relevance, hazard ratios (HRs) of earlier progression or death were estimated across multiple ToDA thresholds (11:00–16:30). Propensity score matching (1:2) was applied to balance baseline characteristics. Result Of the 397 patients, the optimal ToDA cutoff for maximizing progression‐free survival (PFS) benefit was identified as 15:00, with the lowest HR for PFS observed at this threshold. Patients who received immunochemotherapy before 15:00 exhibited significantly longer PFS and overall survival compared to those treated later, with results consistent across pooled and propensity score matching cohorts. Multivariable analysis confirmed early ToDA as an independent prognostic factor for both PFS (adjusted HR, 0.483; 95% CI, 0.357–0.654) and overall survival (adjusted HR, 0.373; 95% CI, 0.265–0.526). Conclusion This study provides real‐world evidence supporting the survival benefit of earlier immunochemotherapy administration in patients with ES‐SCLC. These findings add to the growing body of knowledge on the clinical relevance of circadian timing in cancer treatment. CLINICAL TRIAL REGISTRATION Not applicable 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Extensive-Stage Small Cell Lung Cancer: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Extensive-Stage Small Cell Lung Cancer (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Extensive-Stage%20Small%20Cell%20Lung%20Cancer\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Extensive-Stage Small Cell Lung Cancer\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Extensive-Stage%20Small%20Cell%20Lung%20Cancer\"}]}}"}}]],["$","$L2f",null,{"title":"Extensive-Stage Small Cell Lung Cancer: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Extensive-Stage Small Cell Lung Cancer with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1016/j.jtho.2026.103857","pmid":null,"title":"PP01.123: A Global Phase 3, Double-Blind, Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) Plus Chemotherapy Compared to Atezolizumab Plus Chemotherapy in Patients with First-Line (1L) Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - ROSETTA Lung-01","journal_title":"Journal of Thoracic Oncology","journal_issn":"1556-0864","published_at":"2026-05-07T00:00:00.000Z","url":"https://doi.org/10.1016/j.jtho.2026.103857","source_score":8,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-10","doi":"10.1016/j.jtho.2026.103857","days":"7","issn":"1556-0864","rank":"1","field":"Clinical Medicine","score":"8","category":"Respiratory System","categories":["Respiratory System"],"_categories":["Respiratory System"]},"pubmed":null,"crossref":{"DOI":"10.1016/j.jtho.2026.103857","URL":"https://doi.org/10.1016/j.jtho.2026.103857","ISSN":["1556-0864"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S1556086426003102?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S1556086426003102?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"103857","type":"journal-article","issue":"5","score":1,"title":["PP01.123: A Global Phase 3, Double-Blind, Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) Plus Chemotherapy Compared to Atezolizumab Plus Chemotherapy in Patients with First-Line (1L) Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - ROSETTA Lung-01"],"author":[{"given":"Martin","family":"Reck","sequence":"first","affiliation":[]},{"given":"John","family":"Heymach","sequence":"additional","affiliation":[]},{"given":"Kevin","family":"Franks","sequence":"additional","affiliation":[]},{"given":"Carl","family":"Gay","sequence":"additional","affiliation":[]},{"given":"Vinod","family":"Ganju","sequence":"additional","affiliation":[]},{"given":"Ina","family":"Nordman","sequence":"additional","affiliation":[]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[]},{"given":"Mehmet Ali","family":"Nahit Sendur","sequence":"additional","affiliation":[]},{"given":"Ilhan","family":"Celik","sequence":"additional","affiliation":[]},{"given":"Isaac","family":"Dai","sequence":"additional","affiliation":[]},{"given":"Secil","family":"Koseoglu","sequence":"additional","affiliation":[]},{"given":"Sarita","family":"Koride","sequence":"additional","affiliation":[]},{"given":"Karrie","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Silke","family":"Günther","sequence":"additional","affiliation":[]},{"given":"Özlem","family":"Türeci","sequence":"additional","affiliation":[]},{"given":"Ugur","family":"Sahin","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2026,5]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"21","created":{"date-time":"2026-05-07T16:31:48Z","timestamp":1778171508000,"date-parts":[[2026,5,7]]},"indexed":{"date-time":"2026-05-07T17:13:06Z","timestamp":1778173986454,"date-parts":[[2026,5,7]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S1556086426003102"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"PP01.123: A Global Phase 3, Double-Blind, Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) Plus Chemotherapy Compared to Atezolizumab Plus Chemotherapy in Patients with First-Line (1L) Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - ROSETTA Lung-01"},{"name":"journaltitle","label":"Journal Title","value":"Journal of Thoracic Oncology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jtho.2026.103857"},{"name":"content_type","label":"Content Type","value":"simple-article"},{"name":"copyright","label":"Copyright","value":"Copyright © 2026 Published by Elsevier Inc."}],"deposited":{"date-time":"2026-05-07T17:02:59Z","timestamp":1778173379000,"date-parts":[[2026,5,7]]},"issn-type":[{"type":"print","value":"1556-0864"}],"published":{"date-parts":[[2026,5]]},"publisher":"Elsevier BV","reference":null,"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S1556086426003102"],"article-number":"103857","content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,5]]},"reference-count":0,"published-online":null,"references-count":0,"special_numbering":"S1","short-container-title":["Journal of Thoracic Oncology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/j.jtho.2026.103857","is_oa":false,"title":"PP01.123: A Global Phase 3, Double-Blind, Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) Plus Chemotherapy Compared to Atezolizumab Plus Chemotherapy in Patients with First-Line (1L) Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - ROSETTA Lung-01","updated":"2026-05-08T16:02:47+00:00","published_date":"2026-05-01","best_oa_location":null}},"created_at":"2026-05-11T13:20:55.270Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"brand","value":"Pumitamig","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"brand","value":"Tecentriq","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"condition","value":"Extensive-Stage Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"generic","value":"pumitamig","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"modality","value":"Bispecific Antibody","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"modality","value":"Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"warning","value":"BNT327/BMS-986545 is listed under the brand name 'Pumitamig' per the title; this may be a non-final proprietary name as of the publication date.","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"warning","value":"Study design tag is based on the trial description in the title ('Phase 3, Double-Blind, Randomized Trial'); no protocol or results text was available to confirm.","value_numeric":null},{"paper_doi":"10.1016/j.jtho.2026.103857","tag_type":"warning","value":"The publisher page returned a 404 error — full text, methods, and results are entirely inaccessible. All extracted data comes solely from the paper title and metadata. No efficacy, safety, or patient-level data can be reported.","value_numeric":null}],"summaries":{"what_studied":"A global Phase 3, double-blind, randomized trial (ROSETTA Lung-01) evaluating pumitamig (BNT327/BMS-986545), a PD-L1 × VEGF-A bispecific antibody, plus chemotherapy versus atezolizumab plus chemotherapy in patients with first-line extensive-stage small cell lung cancer (ES-SCLC).","limitations":"Full text is unavailable; only the abstract title and journal metadata were accessible. No results, methods details, or patient data could be extracted."}},{"doi":"10.1002/cncr.70126","pmid":"41355404","title":"Overall survival according to time‐of‐day of immunochemotherapy for extensive‐stage small cell lung cancer","journal_title":"Cancer","journal_issn":"0008-543X","published_at":"2025-12-08T00:00:00.000Z","url":"https://doi.org/10.1002/cncr.70126","source_score":380,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-08","doi":"10.1002/cncr.70126","days":"30","issn":"0008-543X","rank":"3","field":"Clinical Medicine","score":"380","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1002/cncr.70126","title":"Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer.","journal":"Cancer","methods":"This retrospective study (LungTime-R02) analyzed 397 patients with ES-SCLC who received first-line anti-PD-L1 (atezolizumab or durvalumab) plus chemotherapy at our center between May 2019 and October 2023. The time of day of administration (ToDA) was calculated as the median infusion time for each patient's first four ICI treatment cycles. To assess its prognostic relevance, hazard ratios (HRs) of earlier progression or death were estimated across multiple ToDA thresholds (11:00-16:30). Propensity score matching (1:2) was applied to balance baseline characteristics.","results":"","abstract":"$30","keywords":["anti‐PD‐L1","chronotherapy","extensive‐stage small cell lung cancer","immune checkpoint inhibitors","immunochemotherapy","time‐of‐day infusion"],"pubmed_id":"41355404","conclusions":"This study provides real-world evidence supporting the survival benefit of earlier immunochemotherapy administration in patients with ES-SCLC. These findings add to the growing body of knowledge on the clinical relevance of circadian timing in cancer treatment.","publication_date":"2025-12-08T00:00:00"},"crossref":{"DOI":"10.1002/cncr.70126","URL":"https://doi.org/10.1002/cncr.70126","ISSN":["0008-543X","1097-0142"],"link":[{"URL":"https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.70126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"24","score":1,"title":["Overall survival according to time‐of‐day of immunochemotherapy for extensive‐stage small cell lung cancer"],"author":[{"given":"Zhe","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Department of Pathology School of Basic Medical Science Central South University Changsha China"}]},{"given":"Zhaohui","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Third Xiangya Hospital Central South University Changsha China"}]},{"given":"Shidong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Department of Pathology School of Basic Medical Science Central South University Changsha China"}]},{"given":"Nachuan","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Graduate Collaborative Training Base of Hunan Cancer Hospital Hengyang Medical School University of South China Hengyang China"}]},{"given":"Li","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Huan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Jiacheng","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Jun","family":"Deng","sequence":"additional","affiliation":[{"name":"Early Clinical Trial Center Office of National Drug Clinical Trial Institution Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Xue","family":"Chen","sequence":"additional","affiliation":[{"name":"Early Clinical Trial Center Office of National Drug Clinical Trial Institution Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Hua","family":"Xiang","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Liang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"}]},{"given":"Gang","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Pathology Xiangya Hospital School of Basic Medical Sciences Central South University Changsha China"}]},{"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Department of Pathology School of Basic Medical Science Central South University Changsha China"},{"name":"Graduate Collaborative Training Base of Hunan Cancer Hospital Hengyang Medical School University of South China Hengyang China"},{"name":"Early Clinical Trial Center Office of National Drug Clinical Trial Institution Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China"},{"name":"Furong Laboratory Changsha China"}]}],"issued":{"date-parts":[[2025,12,8]]},"member":"311","prefix":"10.1002","source":"Crossref","volume":"131","archive":["Portico"],"created":{"date-time":"2025-12-08T08:01:06Z","timestamp":1765180866000,"date-parts":[[2025,12,8]]},"indexed":{"date-time":"2025-12-23T10:41:55Z","timestamp":1766486515974,"date-parts":[[2025,12,23]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000,"date-parts":[[2025,12,8]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70126"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-07-18"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-17"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-12-08"}],"deposited":{"date-time":"2025-12-23T10:32:25Z","timestamp":1766485945000,"date-parts":[[2025,12,23]]},"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"published":{"date-parts":[[2025,12,8]]},"publisher":"Wiley","reference":[{"DOI":"10.1016/S1470‐2045(21)00546‐5","key":"e_1_2_11_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/jitc‐2023‐008011","key":"e_1_2_11_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.oraloncology.2024.106761","key":"e_1_2_11_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10388‐023‐01006‐y","key":"e_1_2_11_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/hed.27825","key":"e_1_2_11_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtocrr.2024.100659","key":"e_1_2_11_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clgc.2023.06.004","key":"e_1_2_11_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2022.07.1851","key":"e_1_2_11_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2023.01.007","key":"e_1_2_11_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ebiom.2025.105607","key":"e_1_2_11_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.esmoop.2023.102220","key":"e_1_2_11_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1146/annurev.pharmtox.48.113006.094626","key":"e_1_2_11_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2024.04.015","key":"e_1_2_11_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41586‐022‐05605‐0","key":"e_1_2_11_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.trecan.2019.07.002","key":"e_1_2_11_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/0008‐5472.CAN‐24‐2083","key":"e_1_2_11_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtho.2024.11.011","key":"e_1_2_11_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41571‐024‐00914‐x","key":"e_1_2_11_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.annonc.2019.10.021","key":"e_1_2_11_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140‐6736(19)32222‐6","key":"e_1_2_11_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ccell.2024.01.010","key":"e_1_2_11_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ccell.2020.12.014","key":"e_1_2_11_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s13045‐025‐01690‐6","key":"e_1_2_11_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.7326/0003‐4819‐147‐8‐200710160‐00010‐w1","key":"e_1_2_11_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470‐2045(17)30074‐8","key":"e_1_2_11_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/1541‐7786.MCR‐21‐0786","key":"e_1_2_11_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41590‐024‐01859‐0","key":"e_1_2_11_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.cell.2025.03.022","key":"e_1_2_11_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,15]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1002/cncr.70126"],"article-number":"e70126","content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Cancer"],"published-print":{"date-parts":[[2025,12,15]]},"reference-count":28,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,8]]},"references-count":28,"short-container-title":["Cancer"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1002/cncr.70126","is_oa":false,"title":"Overall survival according to time‐of‐day of immunochemotherapy for extensive‐stage small cell lung cancer","updated":"2025-12-09T00:42:45+00:00","published_date":"2025-12-08","best_oa_location":null}},"created_at":"2026-01-08T08:12:02.165Z","updated_at":"2026-01-09T17:12:27.221Z","tags":[{"paper_doi":"10.1002/cncr.70126","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"condition","value":"Extensive-Stage Small Cell Lung Cancer","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"generic","value":"atezolizumab","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"generic","value":"durvalumab","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"modality","value":"PD-L1 Inhibitor","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"sample_size","value":"n=397","value_numeric":397},{"paper_doi":"10.1002/cncr.70126","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"warning","value":"Abstract does not report absolute PFS/OS durations or event counts; only hazard ratios are provided.","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"warning","value":"Single-center retrospective cohort; generalizability may be limited.","value_numeric":null},{"paper_doi":"10.1002/cncr.70126","tag_type":"warning","value":"Time-of-day cutoff (15:00) was selected after scanning multiple thresholds, which can inflate associations.","value_numeric":null}],"summaries":{"what_studied":"A retrospective single-center cohort (n=397) of extensive-stage small cell lung cancer treated first line with anti–PD-L1 (atezolizumab or durvalumab) plus chemotherapy from May 2019 to October 2023, testing whether time-of-day of infusion (median of first four cycles) relates to PFS and OS.","key_result":"The optimal time-of-day cutoff was 15:00; patients treated before 15:00 had longer PFS and OS. Early administration was independently associated with lower risk: PFS adjusted HR 0.483 (95% CI 0.357–0.654) and OS adjusted HR 0.373 (95% CI 0.265–0.526), consistent in pooled and propensity score–matched cohorts.","limitations":"Retrospective, single-center design. The 15:00 threshold was chosen after testing multiple cutoffs (11:00–16:30), raising risk of overfitting.","practice_takeaway":"For ES-SCLC starting PD-L1–based chemoimmunotherapy, scheduling infusions before 15:00 was linked with better PFS and OS in this real-world cohort. When feasible, earlier-day administration may be reasonable while awaiting prospective confirmation."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Extensive-Stage Small Cell Lung Cancer"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Extensive-Stage Small Cell Lung Cancer"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Extensive-Stage Small Cell Lung Cancer"}}}]]

Papers